Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TEM1 CRISPR/Cas9 KO Plasmid (m): sc-427713
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TEM1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TEM1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TEM1 Antibody (G-9): sc-377221
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TEM1 CRISPR/Cas9 KO Plasmid (m) | sc-427713 | 20 µg | $397.00 |
Overview
Cd248 encodes tumor endothelial marker 1 (TEM1), a type I transmembrane glycoprotein enriched in activated pericytes, stromal fibroblasts, and vascular-associated mesenchymal cells. In mouse tissues, TEM1 contributes to cell–matrix interactions and perivascular remodeling, integrating signals linked to extracellular matrix organization, adhesion dynamics, and migratory programs that support angiogenic and fibrotic microenvironments. Cd248 expression is frequently associated with stromal activation in inflammatory and neoplastic settings, where altered pericyte–endothelial crosstalk can influence vessel stabilization and tissue remodeling. Accordingly, Cd248 is widely studied in models of tumor stroma biology, wound repair, and fibrosis-related pathways.
TEM1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cd248 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cd248 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cd248 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TEM1 protein expression.
This CRISPR knockout system enables efficient generation of Cd248-deficient cell models for investigation of TEM1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cd248 exon(s) critical for TEM1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cd248 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TEM1 CRISPR/Cas9 KO Plasmid (m) and TEM1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cd248 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TEM1 HDR Plasmid (m) and TEM1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cd248 homology arms to support homology-directed repair at defined Cd248 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.